Neonc Technologies Holdings, Inc. (NTHI)
Automate Your Wheel Strategy on NTHI
With Tiblio's Option Bot, you can configure your own wheel strategy including NTHI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NTHI
- Rev/Share 0.0057
- Book/Share -0.5307
- PB -8.8569
- Debt/Equity 0.0
- CurrentRatio 0.4074
- ROIC 4.785
- MktCap 89425843.0
- FreeCF/Share -0.3766
- PFCF -13.092
- PE -1.7272
- Debt/Assets 0.0
- DivYield 0
- ROE 5.7409
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.
Published: July 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- In a press release issued earlier today by NeOnc Technologies Holdings, Inc. under the headline, "NeOnc Technologies' Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET," please note "today" in the headline and first paragraph should be "July 24, 2025." The corrected release follows:
Read More
NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform
Published: July 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
CALABASAS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has signed a non-binding term sheet with Quazar Investment to form a new UAE-based investment and clinical platform focused on the Middle East and North Africa (MENA) region.
Read More
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule
Read More
About Neonc Technologies Holdings, Inc. (NTHI)
- IPO Date 2025-03-26
- Website https://www.neonctech.com
- Industry Biotechnology
- CEO Thomas C. Chen
- Employees 8